Literature DB >> 21567223

[Left main intervention: options and limitations in interventional cardiology].

E Boudriot1, H Thiele, G Schuler.   

Abstract

Revascularisation is indicated in patients with left main stenosis (LMS) because of its known positive effect on long-term survival. Coronary artery bypass graft (CABG) surgery has been the traditional procedure of choice for LMS patients, with percutaneous coronary intervention (PCI) being reserved for high-risk surgical patients or for those who have one or more functioning distal bypass grafts (i.e. "protected" left main PCI). Recent studies have re-examined the role of PCI in LMS, however, leading to a recent Class II recommendation for its use in selected patients. The SYNTAX Trial demonstrated that PCI can be performed with good results in the following patient subgroups: patients with isolated LMS, particularly if confined to the ostium; patients with concomitant LMS and isolated single vessel disease; patients with a SYNTAX score of <33; and patients who are at high risk for conventional CABG surgery. Patients with complex coronary anatomy (SYNTAX score >33) or those with concomitant double- or triple-vessel disease are more suited to CABG surgery. Patients who undergo PCI for LMS should be treated in specialized centers with surgical back-up, preferably with patient management decisions being made by a "heart team" consisting of at least one cardiologist and one cardiac surgeon. Ongoing studies are being performed using the hard clinical endpoints of death, myocardial infarction, and stroke in order to further compare the results of PCI vs CABG in LMS patients.

Entities:  

Mesh:

Year:  2011        PMID: 21567223     DOI: 10.1007/s00059-011-3460-5

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  34 in total

1.  Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis.

Authors:  Enno Boudriot; Holger Thiele; Thomas Walther; Christoph Liebetrau; Peter Boeckstegers; Tilmann Pohl; Bruno Reichart; Harald Mudra; Florian Beier; Brigitte Gansera; Franz-Josef Neumann; Michael Gick; Thomas Zietak; Steffen Desch; Gerhard Schuler; Friedrich-Wilhelm Mohr
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery).

Authors:  Kim A Eagle; Robert A Guyton; Ravin Davidoff; Fred H Edwards; Gordon A Ewy; Timothy J Gardner; James C Hart; Howard C Herrmann; L David Hillis; Adolph M Hutter; Bruce Whitney Lytle; Robert A Marlow; William C Nugent; Thomas A Orszulak
Journal:  Circulation       Date:  2004-10-05       Impact factor: 29.690

3.  Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries.

Authors:  Marco Valgimigli; Patrizia Malagutti; Gaston A Rodriguez Granillo; Keiichi Tsuchida; Héctor M Garcia-Garcia; Carlos A G van Mieghem; Willem J Van der Giessen; Pim De Feyter; Peter de Jaegere; Ron T Van Domburg; Patrick W Serruys
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

4.  Comparison of simple and complex stenting techniques in the treatment of unprotected left main coronary artery bifurcation stenosis.

Authors:  Young-Hak Kim; Seong-Wook Park; Myeong-Ki Hong; Duk-Woo Park; Kyoung-Min Park; Bong-Ki Lee; Jong-Min Song; Ki-Hoon Han; Cheol Whan Lee; Duk-Hyun Kang; Jae-Kwan Song; Jae-Joong Kim; Seung-Jung Park
Journal:  Am J Cardiol       Date:  2006-04-07       Impact factor: 2.778

5.  [A new classification of coronary bifurcation lesions].

Authors:  Alfonso Medina; José Suárez de Lezo; Manuel Pan
Journal:  Rev Esp Cardiol       Date:  2006-02       Impact factor: 4.753

6.  Double versus single stenting for coronary bifurcation lesions: a meta-analysis.

Authors:  Demosthenes G Katritsis; George C M Siontis; John P A Ioannidis
Journal:  Circ Cardiovasc Interv       Date:  2009-09-22       Impact factor: 6.546

7.  Stents versus coronary-artery bypass grafting for left main coronary artery disease.

Authors:  Ki Bae Seung; Duk-Woo Park; Young-Hak Kim; Seung-Whan Lee; Cheol Whan Lee; Myeong-Ki Hong; Seong-Wook Park; Sung-Cheol Yun; Hyeon-Cheol Gwon; Myung-Ho Jeong; Yangsoo Jang; Hyo-Soo Kim; Pum Joon Kim; In-Whan Seong; Hun Sik Park; Taehoon Ahn; In-Ho Chae; Seung-Jea Tahk; Wook-Sung Chung; Seung-Jung Park
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

Review 8.  A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis.

Authors:  Hursh Naik; Anthony J White; Tarun Chakravarty; James Forrester; Gregory Fontana; Saibal Kar; Prediman K Shah; Robert E Weiss; Raj Makkar
Journal:  JACC Cardiovasc Interv       Date:  2009-08       Impact factor: 11.195

9.  Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.

Authors:  Julinda Mehilli; Adnan Kastrati; Robert A Byrne; Olga Bruskina; Raisuke Iijima; Stefanie Schulz; Jürgen Pache; Melchior Seyfarth; Steffen Massberg; Karl-Ludwig Laugwitz; Josef Dirschinger; Albert Schömig
Journal:  J Am Coll Cardiol       Date:  2009-05-12       Impact factor: 24.094

10.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.

Authors:  S Yusuf; D Zucker; P Peduzzi; L D Fisher; T Takaro; J W Kennedy; K Davis; T Killip; E Passamani; R Norris
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.